AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22449646
Drug: Medication switch
RxNorm normalized name: witch hazel Medicated Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication switch
Trial: 6375889
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg qid)
Trial: 6375889
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg qid)
Trial: 6375889
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg qid) + Captopril (25 mg qid)
Trial: 16713921
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (90 g total, infused over 3 consecutive days, repeated after 3 months)
Trial: 2628131
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 250 mg orally twice daily for 10 days
Trial: 2628131
Drug: Amoxycillin 250
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 250 mg orally three times daily for 10 days
Trial: 786190
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (No steroid)
Trial: 786190
Drug: Steroid-treated patients
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-treated patients (DMP + MPS)
Trial: 23497981
Drug: 1.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 μg/kg atomized dexmedetomidine
Trial: 21570054
Drug: Systemic cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic cyclosporine (CsA) administered for at least 6 months with a blood CsA concentration of approximately 800 ng/mL.
Trial: 21570054
Drug: Systemic cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic cyclosporine (CsA) administered for at least 6 months.
Trial: 17042889
Drug: l-carnitine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine (15 mg/kg/day)
Trial: 12601631
Drug: Beraprost sodium
RxNorm normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beraprost sodium (3 years treatment)
Trial: 10604887
Drug: h5G1.1‐scFv at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: h5G1.1‐scFv at 2 mg/kg
Trial: 10604887
Drug: h5G1.1‐scFv at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: h5G1.1‐scFv at 1 or 2 mg/kg
Trial: 8542173
Drug: Neoadjuvant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant and primary medical treatment
Trial: 6140091
Drug: prenalterol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prenalterol (40 to 120 mg/day)
Trial: 27253214
Drug: Group psychoeducation
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group psychoeducation (GP) - 10 weekly sessions followed by 8 booster sessions over 2 years
Trial: 25354581
Drug: 1xH5N1‐AS (neutralising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1xH5N1‐AS (neutralising antibodies)
Trial: 25354581
Drug: 2xH5N1‐AS (neutralising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2xH5N1‐AS (neutralising antibodies)
Trial: 17555530
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral risedronate (35 mg) with vitamin D and calcium
Trial: 12432190
Drug: Azithromycin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (5 days treatment)
Trial: 12432190
Drug: Azithromycin (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (14 days treatment)
Trial: 10080586
Drug: Doxorubicin-based neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-based neoadjuvant chemotherapy
Trial: 7030645
Drug: Amcinonide cream
RxNorm normalized name: Amcinonide Cream
DrugBank: Amcinonide (DB00288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amcinonide cream 0.1 percent
Trial: 7030645
Drug: Halcinonide cream
RxNorm normalized name: Halcinonide Cream
DrugBank: Halcinonide (DB06786)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Halcinonide cream 0.1 percent
Trial: 31347002
Drug: Triple puncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple puncture treatment (6 times per week for 4 weeks)
Trial: 31347002
Drug: Carbamazepine (300‐600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (300‐600 mg per day for at least 1 month)
Trial: 29566104
Drug: Everolimus plus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus plus Letrozole (10 mg/d + 2.5 mg/d) in first-line treatment
Trial: 29566104
Drug: Everolimus plus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus plus Exemestane (10 mg/d + 25 mg/d) in second-line treatment
Trial: 29566104
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events in first-line treatment
Trial: 29566104
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events in second-line treatment
Trial: 22555350
Drug: Comprehensive oral
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive oral care protocol (tongue scraping, electric toothbrushing, moisturizing)
Trial: 22555350
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral care protocol (manual toothbrushing)
Trial: 20681276
Drug: Gingko biloba
RxNorm normalized name: Gingko Biloba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gingko biloba Tablet (GBT)
Trial: 16275189
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine (50 to 70 mug/kg/min)
Trial: 10500058
Drug: Rofecoxib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (50 mg once daily)
Trial: 8953672
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g bolus dose)
Trial: 8953672
Drug: Lymecycline (10-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline (10-day course of 300 mg twice daily)
Trial: 1834805
Drug: Fibrinolysis and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolysis and aspirin combined
Trial: 7046098
Drug: Pirenzepine 100
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 100 mg daily
Trial: 25986943
Drug: 10-day quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day quadruple anti-H. pylori treatment with a single dosage of omeprazole and bismuth
Trial: 25986943
Drug: Lookalike placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lookalike placebos with a single dosage of omeprazole and bismuth
Trial: 20586002
Drug: 3.75 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 microg antigen with 50% of the standard MF59 dose (group A)
Trial: 20586002
Drug: 7.5 microg
RxNorm normalized name: Levonorgestrel 37.5 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 microg antigen and 100% standard MF59 dose (group B)
Trial: 17354223
Drug: Intraperitoneal (IP)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (IP) administration of yttrium‐90‐labeled murine monoclonal antibody HMFG1 ((90)Y‐muHMFG1)
Trial: 15689218
Drug: 5% Dead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Dead Sea salt solution (Mavena(R) Dermaline Mg(46) Dead Sea salt) for 15 minutes
Trial: 15689218
Drug: 5% Dead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Dead Sea salt solution
Trial: 12196422
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nateglinide and troglitazone
Trial: 8129216
Drug: Double-blind, placebo-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind, placebo-controlled oral challenge test
Trial: 2774259
Drug: liquids, up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquids, up to 5 ml/kg + placebo (glucose water 0.2 ml/kg)
Trial: 2774259
Drug: liquids, up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquids, up to 5 ml/kg + ranitidine 2 mg/kg in glucose water 0.2 ml/kg
Trial: 16710349
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g cholestyramine
Trial: 3373260
Drug: 24-hour infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour infusion of weekly fluorouracil (5-FU) at a dose of 750 mg/m2 incrementally increased to 3,400 mg/m2
Trial: 3373260
Drug: 24-hour infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour infusion of weekly fluorouracil (5-FU) plus N-(phosphonacetyl)-L-aspartic acid (PALA) administered as an IV bolus over 15 minutes at a fixed dose of 250 mg/m2
Trial: 30912860
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) and Monitor-Only (MO)
Trial: 19690066
Drug: rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 8 mg daily for 16 weeks
Trial: 11585270
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: Ondansetron 8 mg i.v. at 4-h intervals plus dexamethasone 20 mg i.v. from the start of CT, followed by dexamethasone 5 mg i.v. every 12 h until CT was complete.
Trial: 11585270
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: Same treatment as arm A but with ondansetron 8 mg i.v. given at 24-h intervals.
Trial: 6500902
Drug: Bornaprine 8
RxNorm normalized name: bornaprine
DrugBank: Bornaprine (DB13619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bornaprine 8 mg daily
Trial: 6500902
Drug: Bornaprine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bornaprine (various rising doses)
Trial: 31413233
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of Hericium erinaceus for 12 weeks
Trial: 30589045
Drug: OxyContin 10
RxNorm normalized name: OxyContin 10mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OxyContin 10 mg orally, adjusted according to pain relief
Trial: 19136369
Drug: Golimumab (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab (50, 100, or 200 mg)
Trial: 11424316
Drug: Clarithromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (200 mg b.i.d.), amoxicillin (500 mg q.i.d.), and lansoprazole (30 mg b.i.d.) for 5 days
Trial: 11424316
Drug: Clarithromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (200 mg b.i.d.), amoxicillin (500 mg q.i.d.), and lansoprazole (30 mg b.i.d.) for 7 days
Trial: 9663361
Drug: 2% dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% dorzolamide administered topically TID
Trial: 9663361
Drug: 0.5% betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% betaxolol administered topically BID plus placebo administered topically QD
Trial: 959332
Drug: Bronchodilator and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator and bronchial drainage
Trial: 959332
Drug: Bronchodilator/mucolytic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator/mucolytic agents and bronchial drainage
Trial: 959332
Drug: Mucolytic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucolytic agent with bronchial drainage
Trial: 959332
Drug: Comparison among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison among three treatments
Trial: 31002537
Drug: GP2017 (adalimumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP2017 (adalimumab biosimilar) 40 mg subcutaneous injection
Trial: 25406528
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg kg‐1 day‐1 (placebo)
Trial: 25406528
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg kg‐1 day‐1
Trial: 25406528
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg kg‐1 day‐1
Trial: 23004236
Drug: All fit
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All fit SSO implants
Trial: 23004236
Drug: SPI contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPI contact implants
Trial: 23004236
Drug: SPI element
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPI element implants
Trial: 19672180
Drug: Standard practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard practice group (BIS recorded but not guiding drug administration)
Trial: 10735015
Drug: Treatment comparable
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment comparable to white women
Trial: 9311629
Drug: Ritonavir with
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir with fluconazole (400 mg on day 1, 200 mg every day on days 2-5)
Trial: 9311629
Drug: Ritonavir alone
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir alone (200 mg every 6 hr for 4 days)
Trial: 24162762
Drug: Intra‐articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra‐articular hyaluronic acid injections (2 cycles of 5 weekly injections at 6-month intervals) after high tibial osteotomy (HTO)
Trial: 24162762
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intra‐articular injections after HTO)
Trial: 24162762
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group (intra‐articular hyaluronic acid injections)
Trial: 22430450
Drug: Tight glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycemic control with insulin (target BGC 4‐6 mmol/L)
Trial: 22430450
Drug: Standard practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard practice (restrictive guidelines for starting insulin, target BGC 8‐10 mmol/L)
Trial: 1859906
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen therapy
Trial: 11954868
Drug: IFNbeta‐1 b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1 b combined with monthly intravenous methylprednisolone (MP)
Trial: 11954868
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (IFNbeta‐1 b + MP)
Trial: 10375338
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy with conjugated equine estrogen, 0.3 mg/d, and medroxyprogesterone, 2.5 mg/d
Trial: 6775954
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg chenodeoxycholic acid (4 X 125 mg gelatin‐coated capsules)
Trial: 6775954
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg chenodeoxycholic acid
Trial: 6775954
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg chenodeoxycholic acid
Trial: 6775954
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg chenodeoxycholic acid
Trial: 30307514
Drug: Medium cut-off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium cut-off dialyzers (with extended middle molecule removal) during hemodialysis
Trial: 26087610
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night
Trial: 23351813
Drug: Partial oral
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial oral treatment with antibiotics after a minimum of 10 days of parenteral treatment.
Trial: 23351813
Drug: Full parenteral
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full parenteral treatment (unchanged parenteral therapy).
Trial: 17593859
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (10 microg/kg) plus IV PCA morphine
Trial: 17593859
Drug: IV PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA morphine alone
Trial: 15220231
Drug: INS +
RxNorm normalized name: Eye Vitamins + Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS + MET (dual therapy)
Trial: 15220231
Drug: INS +
RxNorm normalized name: Eye Vitamins + Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS + TGZ (dual therapy)
Trial: 15220231
Drug: INS +
RxNorm normalized name: Eye Vitamins + Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS + MET, add TGZ (triple therapy)
Trial: 15220231
Drug: INS +
RxNorm normalized name: Eye Vitamins + Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS + TGZ, add MET (triple therapy)
Trial: 15220231
Drug: INS +
RxNorm normalized name: Eye Vitamins + Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS + TGZ add MET (triple therapy)
Trial: 15220231
Drug: INS +
RxNorm normalized name: Eye Vitamins + Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS + MET add TGZ (triple therapy)
Trial: 2679483
Drug: Adjunctive amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive amitriptyline hydrochloride
Trial: 2679483
Drug: Adjunctive desipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive desipramine hydrochloride
Trial: 168120
Drug: Chloroquine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (500 mg daily for 10 weeks)
Trial: 168120
Drug: Metronidazole (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (750 mg three times daily for 10 days)
Trial: 31166383
Drug: Lung-protective ventilation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung-protective ventilation (PV group) with 7 mL/kg tidal volume and personal level of PEEP
Trial: 31166383
Drug: Conventional ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilation (CV group) with 10 mL/kg tidal volume without PEEP
Trial: 23204161
Drug: Specific ART
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific ART medications (e.g., atazanavir, atazanavir/ritonavir, fosamprenavir, indinavir, indinavir/ritonavir, lopinavir/ritonavir)
Trial: 21421658
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (200 mg, single oral dose)
Trial: 21421658
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (200 mg, o.d.) and Vitamin C (150 mg, o.d.)
Trial: 1732771
Drug: Active management
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active management of labor (amniotomy within one hour of diagnosis, oxytocin infusion starting at 6 mU/min, increasing to a maximum of 36 mU/min)
Trial: 6431939
Drug: Nonpharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacological treatment
Trial: 22154650
Drug: Ifosfamide/actinomycin/vincristine-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide/actinomycin/vincristine-based chemotherapy with local therapy (radiotherapy or surgery)
Trial: 19924786
Drug: No local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No local therapy
Trial: 12569115
Drug: Bifidobacteria-fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacteria-fermented milk (BFM), 100 mL/day for one year
Trial: 9316009
Drug: Intravenous carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous carboplatin (CBDCA) 400 mg/m2 on day 1 and oral etoposide 50 mg/m2 on days 1-21 (Group I)
Trial: 9316009
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide 50 mg/m2 on days 1-21 alone (Group II)